Subscribe To
aravive (arav) upgraded to strong buy: what does it mean for the stock?
aravive (ARAV) might move higher on growing optimism about its earnings prospects, which is reflected b...
October 13, 2023, 1:31 pm
aravive (arav) reports q2 loss, tops revenue estimates
aravive (ARAV) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of...
August 21, 2023, 7:32 pm
Why is aravive (arav) stock down 58% today?
aravive (NASDAQ: ARAV ) stock is plummeting on Thursday following the release of results from a Phase ...
August 3, 2023, 8:34 am
Are medical stocks lagging boston scientific (bsx) this year?
Here is how Boston Scientific (BSX) and aravive (ARAV) have performed compared to their sector so far t...
May 15, 2023, 11:26 am
aravive to host virtual kol event on its late-stage oncology asset batiraxcept
Webinar to take place on Wednesday, May 24, 2023 at 1:00pm ET HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) — aravi...
May 8, 2023, 11:05 am
aravive announces poster presentation on batiraxcept at 2023 asco annual meeting
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) — aravive, Inc. (Nasdaq: ARAV, “the Company”), a late cl...
April 26, 2023, 9:00 pm
What makes aravive (arav) a new buy stock
aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the compan...
April 17, 2023, 1:43 pm
aravive (arav) reports q4 loss, tops revenue estimates
aravive (ARAV) delivered earnings and revenue surprises of -39.39% and 298.38%, respectively, for the q...
March 15, 2023, 9:56 am
aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clin...
February 13, 2023, 5:00 pm
aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clin...
February 13, 2023, 5:00 pm
aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clin...
February 13, 2023, 5:00 pm
aravive: down but not out with pivotal ovarian data due in 2023
aravive shareholders have been heavily diluted and suffered substantial losses in 2022. The company has...
December 14, 2022, 8:45 am
aravive (arav) reports q4 loss, misses revenue estimates
aravive (ARAV) delivered earnings and revenue surprises of 3.12% and 36.74%, respectively, for the quar...
March 31, 2022, 6:48 pm
aravive highlights updated batiraxcept data from kidney cancer trial
aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/...
March 3, 2022, 10:06 am
aravive highlights updated batiraxcept data from kidney cancer trial
aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/...
March 3, 2022, 10:06 am
aravive highlights updated batiraxcept data from kidney cancer trial
aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/...
March 3, 2022, 10:06 am
aravive (arav) upgraded to buy: here's why
aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the compan...
February 10, 2022, 1:05 pm
aravive (arav) upgraded to buy: here's why
aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the compan...
February 10, 2022, 1:05 pm
aravive (arav) upgraded to buy: here's why
aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the compan...
February 10, 2022, 1:05 pm
Is aravive (arav) outperforming other medical stocks this year?
Here is how aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector s...
February 10, 2022, 10:46 am